Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF) on Tuesday (April 13) said his country will have the capacity to manufacture 50 million COVID dose by this summer. This comes on the day when the Drugs Controller General of India (DCGI) approved the Russian vaccine approval for restricted use in India.
On Monday, a Subject Expert Committee (SEC) met to discuss Russia’s Sputnik V application for emergency use authorisation in India. The committee of experts later gave their recommendations and sent DCGI for a final nod on April 12.
According to the official release by the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), India became the sixtieth country in the world to give a go-ahead to Sputnik V.
“The vaccine has been registered in India under the emergency use authorization procedure based on results of clinical trials in Russia as well as positive data of additional Phase III local clinical trials in India conducted in partnership with Dr. Reddy’s Laboratories,” said RDIF.
The vaccine has an efficacy rate of 91. 6 per cent and has already been approved in several countries. RDIF has reached agreements with the pharmaceutical companies in India like Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech to produce more than 850 million doses per year.